Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Touts CNS-Focused Branded Pipeline, Expects 15 Filings By 2015

Executive Summary

Teva's expansion of its branded drug business will focus on central nervous system therapies, with one of its first regulatory submissions, an NDA for a 40 mg/day dose of multiple sclerosis treatment Copaxone,slated for 2009

You may also be interested in...

Generic Plavix Will Slow U.S. Pharmaceutical Sales Growth In 2006 – IMS

The launch of generic Plavix (clopidogrel) could reduce overall pharmaceutical sales growth for 2006 by nearly one percent, IMS Health VP-Industry Relations Doug Long suggested

Teva Phase IV Study For Parkinson’s Drug Azilect Looks Into Melanoma Risk

Teva will conduct a postmarketing study of its Parkinson's disease drug Azilect (rasagiline) to investigate the risk of melanoma

Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics

Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts